Solutions for TME Heterogeneity
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology provides a full range of solutions for the study of tumor microenvironment heterogeneity, helping researchers successfully achieve their research goals.
Tumors can be thought of as highly heterogeneous functional tissues, connected and dependent on the microenvironment. However, the microenvironment changes during the transformation of cells into cancer cells, which makes it easier for cancer cells to develop in the body. This microenvironmental change includes three aspects, namely the generation of fibroblasts, the migration of immune cells and the development of the vasculature. Such differences in the microenvironment result that only tumor cells with certain mutations can survive well, which further results in tumor heterogeneity. These changes can determine tumor cell morphology, function, aggressiveness, and response to therapy, as well as accurately assess patient prognosis. Therefore, the occurrence and development of tumors are not only dependent on genetic mutations, but also related to the heterogeneity of the tumor microenvironment.
At present, many studies focus on the immune heterogeneity of the tumor microenvironment. However, research strategies targeting the tumor microenvironment are not comprehensive enough and face many challenges, including determining the composition of the tumor microenvironment, the dynamic changes in the heterogeneity of the tumor microenvironment, and the relationship between heterogeneity and tumorigenesis/metastasis, the relationship between heterogeneity and drug treatment, etc. In addition, a series of linkages between genes, proteins and cells in the TME, which has the potential to be a target for diagnosis and therapy, could lead to the development of targeted therapies based on the heterogeneity of the tumor microenvironment. Alfa Oncology is developing various technologies to solve the above problems, hoping to break through the research of tumor microenvironment heterogeneity and drug discovery problems, and provide corresponding diagnostic methods or clinical medication guidance.
At present, Alfa Oncology mainly uses imaging mass spectrometry, single-cell omics technology, proteomics and transcriptomics to study the heterogeneity of tumor microenvironment.
Imaging mass spectrometry. The microenvironment of cancer includes normal cells, tumor cells, connective tissue, blood vessels, and inflammation, as well as state changes at different time points. These constituents have their own unique compound molecular characteristics. Investigators' analysis of disease states relies heavily on the interpretation of histopathology and the establishment of molecular profiles depicting biological effects. Innovative imaging mass spectrometry techniques can cater to these problems and solve them.
Single-cell omics technology. During the evolution of cancer, there is a genetic diversification of proliferating subpopulations of malignant cells. Single-cell multi-omics technology integrates multiple data models, which can provide massive information of different dimensions for tumor microenvironment research, and provide an important basis for a comprehensive understanding of the evolution mechanism of tumor microenvironment and tumor development.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.